Board of Directors
Our Board is comprised of senior executives from successful pharmaceutical and investment companies.
Mr. Mathias has more than 30 years of experience in the healthcare industry as an entrepreneur, investor and banker. Over the course of his career, he has raised over $250 million in debt and equity for pharmaceutical and healthcare technology and services companies. For 15 years prior to joining Thetis full-time as CEO, Mr. Mathias was a senior partner at the investment bank Carter Morse & Mathias (Southport, Connecticut), where he led the bank’s Healthcare Group. He previously was a senior vice president in the Healthcare Group at GE Equity Capital, Chief Operating Officer of Diabetes Support Systems, and executive vice president of Premier Healthcare, a healthcare focused private equity firm.
He has served on the board of various organizations in the healthcare space, including the Connecticut Venture Group, Western Connecticut Health Network, Diabetes Support Systems and Dome Imaging Systems. He also served as Chairman of the Alliance of International Corporate Advisors (AICA), a network of investment banks in the Americas, Europe and Asia focused on mid-market M&A transactions and capital raises.
Mr. Mathias has an MBA from the Yale School of Management, a BA in Economics from Harvard College, and was a Fulbright Fellow in economic development.
Dr. Sciavolino has extensive experience in the pharmaceutical industry, including a distinguished 35 year career at Pfizer Global R&D. At Pfizer, Dr. Sciavolino held various management roles and responsibilities in drug discovery, development, registration and licensing, culminating in a role as Vice President of R&D Operations, in which he oversaw a team of 1,000 scientists in the United States, Europe and Asia. He was the enabling force behind two of Pfizer’s most notable franchises, Zithromax and Celebrex. After leading the discovery chemistry team responsible for the initial macrolide antibiotic research, he served as principal investigator leading the Phase I evaluation of 11 compounds in first-in-human (FIH) studies, which led to the identification and development of Zithromax, an antibiotic considered one of the most important new drugs of the 20th century. He also played a major role in the licensing of Celebrex, a COX-2 inhibitor that reached $3 billion in peak annual sales globally.
Dr. Sciavolino has served on numerous editorial boards including Annual Reports in Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and the Journal of Antibiotics. Dr. Sciavolino has more than 30 issued patents and has a Ph.D. in organic chemistry from the University of Michigan and B.S. in Pharmacy from St. John’s University.
Mr. Wurzer is Executive Vice President and Chief Investment Officer at Connecticut Innovations Inc., a leading early stage life science investor nationwide. Prior to joining CI, Mr. Wurzer had extensive senior-level experience in operations and finance, including more than 10 years as executive vice president, treasurer and CFO of CuraGen Corporation (NASDAQ: CRGN), where he guided the company through its initial public offering, raising more than $700 million, and through the negotiation of strategic and business development alliances with Roche, Bayer and Abgenix. He helped to grow CuraGen and its technology development subsidiary into an operation with more than 500 employees and a market capitalization as high as $5.3 billion. Dave began his professional career with Coopers & Lybrand in Hartford, Connecticut.
Walter Ogier co-founded Harvard-affiliated Acetylon Pharmaceuticals (Boston MA, oncology and neurodegeneration) in 2008 and served as its President & CEO until its sale to Celgene in 2016. He subsequently served as founding President & CEO of Regenacy Pharmaceuticals (neuropathy and hemoglobinopathies), which was spun out of Acetylon at the time of the Celgene acquisition. In addition to continuing to serve a Director and consultant/advisor to Regenacy, Mr. Ogier currently serves as a Director of Thetis Pharmaceuticals (Branford CT, gastroenterology), a Director of privately-held Biothera Pharmaceuticals (Eagan MN, immuno-oncology), and as an advisor/mentor to several emerging biopharmaceutical companies. Mr. Ogier brings more than 30 years of biopharmaceutical / biomedical industry experience to his Board and advisory roles, including a decade with Baxter Healthcare Corporation (Deerfield IL, stem cells, immuno-oncology, cell therapy and medical devices) in product management and business development executive roles, with Aastrom Biosciences (Ann Arbor MI, cell therapy) as VP Marketing leading to a successful IPO, and in subsequent President & CEO roles with Eligix (Medford MA, stem cells and cell therapy, sold to BioTransplant), Genetix/bluebird bio (Cambridge MA, stem cell gene therapy, Nasdaq: BLUE), and Arbios Systems (Waltham, MA, liver dialysis). Mr. Ogier received a BA magna cum laude in chemistry from Williams College and an MBA from the Yale School of Management.
Dr. Lennox has been an active investor and entrepreneur in early stage life science companies for over twenty five years. He has served on the boards of over eighteen companies including General Surgical Innovations, Inc (acquired by Tyco International Corp), GeneOhm Sciences, Inc. (acquired by Becton Dickinson and Co.) and Applied Molecular Evolution, Inc. (acquired by Eli Lilly Corp.). He has been involved in the founding of seven companies, six of which were successful. He was founding CEO of Protometrix, Inc. (acquired by Life Technologies, Inc.), and also of CGI Pharmaceuticals, Inc. (acquired by Gilead Sciences, Inc.). He was founding Chairman of Amicus Therapeutics, Inc. (NASDAQ: FOLD). He was a founder and served as Executive Chairman of Bikam Pharmaceuticals, Inc., engineering the sale of the company to Shire Pharmaceuticals PLC in 2014. He also helped found polyGenomics, Inc., American Renal Associates, Inc., and Biorelix, Inc. Eleven additional companies he led investments in had successful IPOs including i-STAT Corp, Cephalon, Inc., British Biotechnology, Ltd., and Threshold Pharmaceuticals, Inc.
Ron began his venture capital career with Hancock Venture Partners (now Harbourvest Partners). He was a founding partner at CHL Medical Partners which raised three successive funds from institutional investors. He is an Entrepreneur in Residence with Yale University’s Office of Co-operative Research and Mount Sinai Innovation Partners. In addition to his role at Thetis, he is a director of RadImmune Pharmaceuticals, Inc.
Ron holds a B.Sc. in Molecular Biology from the University of Glasgow, a D.Phil in Cell Biology from Oxford University and an MBA from The Wharton School of the University of Pennsylvania.
Mr. Willson is President & CEO of ITF Pharma, Inc. and is co-founder and chairman of Hsiri Therapeutics, LLC, a start-up company focused on the development of new antibiotics for drug-resistant infections. He was formerly the President & CEO of Cytokine PharmaSciences, Inc., a biopharmaceutical company focused on women’s health, inflammation and cancer. As one of Cytokine founders, Mr. Willson spent 19 years in leadership positions managing the successful development and licensing of several products, including Cervidil, one of the world’s leading obstetric products. In October 2011, Mr. Willson led the company in a strategic sale to Ferring S.A. Before joining Cytokine, Mr. Willson held management, finance and business development positions at Abbott Laboratories Rorer International, and Carrington Laboratories. Mr. Willson graduated summa cum laude from the University of Notre Dame with a degree in psychology and modern languages and has a law degree from the University of California, Hastings College of the Law.